Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Codexis, Inc. (4QK.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
6.06+0.30 (+5.28%)
At close: 09:55PM CET
Advertisement

Codexis, Inc.

200 Penobscot Drive
Redwood City, CA 94063
United States
650 421 8100
https://www.codexis.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees261

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephen George Dilly MBBS, Ph.D.Pres, CEO & Director75kN/A1960
Mr. Ross Taylor Jr., M.B.A.Sr. VP & CFO667.31kN/A1963
Mr. John J. NicolsDirector & Strategic Advisor1.33M5.18M1964
Mr. Kevin Norrett M.B.A., M.S.Chief Operating OfficerN/AN/A1973
Ms. Asli Aras Ph.D.VP & Head of Corp. Devel.N/AN/AN/A
Ms. Karen Frechou-ArmijoSr. VP & Head of HRN/AN/AN/A
Dr. Gjalt Huisman Ph.D.Sr. VP of Strategic Devel. & GM of BiotherapeuticsN/AN/AN/A
Mr. Rob Wilson Ph.D.Sr. VP & GM of Performance EnzymesN/AN/AN/A
Dr. Karl A. Schoene Ph.D.Sr. VP of Devel. & OperationsN/AN/AN/A
Dr. Stefan Lutz Ph.D.Sr. VP of ResearchN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Corporate Governance

Codexis, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 5. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 7; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement